FDA Commissioner Marty Makary and Vinay Prasad, director of the Center for Biologics Evaluation and Research (CBER), describe ...

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be ...

Trenton M. Johnson is a seasoned project management leader with 27+ years of experience working in the biopharma industry ...

The growth of the stronger product – which now accounts for more than a quarter of Eylea sales – allowed Bayer to predict ...

Alkermes already has positive results for alixorexton in NT1 from the phase 2 Vibrance-1, while Takeda is developing another ...

Generative AI models aren’t perfect. Despite constant improvement, they still hallucinate and make mistakes. And for a ...

In type 1 diabetes, the CGM has been paired with automated insulin delivery, and we've closed the loop and dramatically ...

The UK government has set out an ambitious plan to phase out animal testing in scientific studies within five years, with ...

The absorption of NHS England into the DHSC is expected to be completed within two years and end "the duplication of two organisations doing the same job," according to the government. It also said ...

Pazdur, who currently leads the FDA's Oncology Center of Excellence (OCE) and has been with the agency for more than 25 years ...

The $6.7 billion merger brought together two companies that had been forced to file for bankruptcy protection due to opioid ...